Pregled bibliografske jedinice broj: 635688
Equal response of adolescent monozygotic twins suffering from a first episode of schizophrenia to a risperidone long-acting injectable antipsychotic
Equal response of adolescent monozygotic twins suffering from a first episode of schizophrenia to a risperidone long-acting injectable antipsychotic // Abstract CD-ROM / WFSBP (ur.).
Kyoto: World Federation of Societies of Biological Psychiatry, 2013. str. n.a.-n.a. (poster, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 635688 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Equal response of adolescent monozygotic twins suffering from a first episode of schizophrenia to a risperidone long-acting injectable antipsychotic
Autori
Petrić, Daniela ; Vučić Peitl, Marija ; Peitl, Vjekoslav ; Prološčić, Joško ; Frančišković, Tanja
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
Abstract CD-ROM
/ WFSBP - Kyoto : World Federation of Societies of Biological Psychiatry, 2013, N.a.-n.a.
Skup
11th World Congress of Biological Psychiatry
Mjesto i datum
Kyoto, Japan, 23.06.2013. - 27.06.2013
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
twins ; schizophrenia ; long acting drugs
Sažetak
Objective Aim of the research was to examine the treatment response to a risperidone long- acting injectable antipsychotic of adolescent monozygotic female twins suffering from a first episode of schizophrenia. Twin research studies performed so far showed high concordance rated for schizophrenia, which are as high as 40-50% for monozygotic twins (Mata et al, 2001 ; Jakovljevic, 2011). Also, there is a growing body of knowledge supporting the role of neurotransmitter genetic variations which may influence clinical response to different psychopharmacologic agents (Zhang et al, 2010). Method Assessment started in 2010 when the twin patients were 16 years old and diagnosed with schizophrenia in accordance with the Kiddie- Sads-Present and Lifetime version (K-SADS-PL) semi-structured interview. Effectiveness of the therapy was assessed using clinical scales: Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression – Severity of Illness Scale (CGI-S), Clinical Global Impression – Improvement Scale (CGI-I), Children’s Global Assessment Scale (CGAS). Results Both twins showed improvement in positive, negative and cognitive symptoms and are now functioning normally and without symptoms. Their response to risperidone was similar, as well as their symptom improvement. Conclusion Genetic factors can be an important factor when predicting treatment efficiency of risperidone, as well as other antipsychotic agents.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka
Profili:
Daniela Petrić
(autor)
Tanja Frančišković
(autor)
Vjekoslav Peitl
(autor)
Marija Vučić Peitl
(autor)
Joško Prološčić
(autor)